サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1784039

精密ゲノム検査の世界市場

Precision Genomic Testing

出版日
ページ情報
英文 222 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.98円
精密ゲノム検査の世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 222 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

精密ゲノム検査の世界市場は2030年までに423億米ドルに達する見込み

2024年に167億米ドルと推定される精密ゲノム検査の世界市場は、2024～2030年の分析期間中に16.7%のCAGRで成長し、2030年には423億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるゲノム検査消耗品は、CAGR18.2%を記録し、分析期間終了までに246億米ドルに達すると予測されます。ゲノム検査機器セグメントの成長率は、分析期間中CAGR 15.3%と推定されます。

米国市場は44億米ドルと推定、中国はCAGR15.7%で成長予測

米国の精密ゲノム検査市場は、2024年に44億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに65億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは15.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ15.6%と14.3%と予測されています。欧州では、ドイツがCAGR約12.1%で成長すると予測されています。

世界の精密ゲノム検査市場- 主要動向と促進要因のまとめ

精密ゲノム検査はどのようにヘルスケアを変革するのか？

精密ゲノム検査は、個別化診断、標的治療、病気の早期発見を可能にすることで、現代医療に革命をもたらしています。個人の遺伝子構成を分析することで、ヘルスケアプロバイダーは遺伝的変異に基づいて治療を調整し、患者の転帰を大幅に改善することができます。このアプローチは、特に腫瘍学、希少疾患、薬理ゲノミクス、生殖医療において大きな影響力を持ち、そこでは遺伝的洞察が治療の決定において重要な役割を果たします。

次世代シーケンサー（NGS）、CRISPRベースの遺伝子編集、AI主導のバイオインフォマティクスの拡大により、様々な医療分野で精密ゲノム検査の導入が加速しています。全ゲノムシーケンス（WGS）、全エクソームシーケンス（WES）、リキッドバイオプシー技術の進歩により診断精度が向上し、ゲノム検査がより身近で費用対効果の高いものとなっています。遺伝子研究が進化を続ける中、プロテオミクスやメタボロミクスを含むマルチオミクス・アプローチの統合が、精密医療アプリケーションをさらに洗練させています。

精密ゲノム検査の成長を牽引する市場動向とは？

精密ゲノム検査市場を形成する最も重要な動向の一つは、個別化医療に対する需要の高まりです。遺伝子の違いが薬物反応に影響を与えるという認識が広まり、遺伝子プロファイルに基づいて個人に最も効果的な薬剤を決定するファーマコゲノミクスの拡大に拍車がかかっています。これは、遺伝的要因が治療効果に大きく影響する腫瘍学、循環器学、神経学などの分野で特に重要です。

もう一つの重要な動向は、DTC（Direct-to-Consumer）遺伝子検査の採用が増加していることです。家系、疾病リスク評価、ライフスタイル推奨のための家庭用ゲノム検査キットを提供する企業が人気を博し、市場拡大の原動力となっています。しかし、規制当局の監視やデータプライバシーに関する倫理的な懸念は、この分野における重要な課題として残っています。

AIとビッグデータ解析の進歩もゲノム検査の展望を変えつつあります。膨大なゲノムデータの解釈に機械学習アルゴリズムが使用され、疾患リスク予測やバイオマーカー探索の精度が向上しています。さらに、クラウドベースのゲノムデータベースが大規模な遺伝子研究を促進し、複雑な疾患や潜在的な治療標的の研究を加速させています。

精密ゲノム検査の導入でリードしている地域は？

北米が精密ゲノム検査市場を独占しており、強力な研究資金、個別化医療の高い採用率、高度なヘルスケアインフラがその原動力となっています。米国は、ゲノミクス研究への多額の投資、All of Us Research Programのような政府のイニシアティブ、バイオ企業と学術機関のコラボレーションでリードしています。

欧州も主要なプレーヤーであり、規制当局の支援、官民パートナーシップ、遺伝子検査の臨床的利益に対する認識の高まりから恩恵を受けています。ドイツ、英国、フランスなどの国々は、患者のケアを改善するためにゲノムデータをヘルスケアシステムに統合することに重点を置き、精密医療への取り組みを進めています。

アジア太平洋では、バイオテクノロジーへの投資の増加、ヘルスケアへのアクセスの拡大、精密医療を推進する政府のイニシアチブに後押しされ、ゲノム検査が急成長しています。中国、日本、韓国は、ゲノムデータの収集と解析に特化した国家プログラムを持ち、この地域のゲノム研究の取り組みをリードしています。一方、ラテンアメリカや中東の新興市場でも徐々に精密ゲノム検査の導入が進んでいるが、高額なコストや限られたインフラといった課題が依然として普及の障壁となっています。

精密ゲノム検査市場の成長はいくつかの要因によって牽引されている

市場成長の主な促進要因の1つは、遺伝性疾患や、がん、神経変性疾患、心血管疾患などの複合疾患の有病率の増加です。ヘルスケアにおいて早期発見とリスク評価がより重要になるにつれて、ゲノム検査は予防対策と精密治療の指針として不可欠な役割を果たしています。

コスト効率の高い超高速シーケンシング技術の開発など、シーケンシングプラットフォームの技術的進歩により、ゲノム検査はより身近なものとなっています。ポータブルシーケンスデバイスと自動ワークフローの出現は、精密医療の範囲を専門検査室だけでなく、臨床現場やポイントオブケア診断にまでさらに拡大しつつあります。

規制当局の支援と資金提供イニシアティブも市場導入を加速しています。世界各国の政府は、国家ゲノムデータベースと精密医療プログラムに投資し、ヘルスケアプロバイダー、研究機関、バイオテクノロジー企業間の連携を促進しています。加えて、遺伝子検査に対する償還政策も進化しており、ゲノムに基づく診断への手頃な価格と患者のアクセスが改善されつつあります。

ゲノミクスの分野が進歩し続ける中、AI、クラウド・コンピューティング、分子生物学の融合は、精密ゲノム検査の能力をさらに高めると思われます。疾病管理、医薬品開発、予防ヘルスケアを再定義する可能性を秘めたこの市場は、世界の個別化医療の未来を形成し、大きく成長する態勢を整えています。

セグメント

タイプ（ゲノム検査消耗品、ゲノム検査機器、ゲノム検査サービス）、技術タイプ（次世代シーケンス技術、ポリメラーゼ連鎖反応技術、マイクロアレイ技術、サンガーシーケンス技術、CRISPR/CASシステム技術、その他の技術タイプ）、用途（腫瘍学用途、心血管疾患用途、神経疾患用途、生殖医療用途、希少疾患用途、その他用途）、最終用途（病院・クリニック最終用途、診断研究所最終用途、研究・学術機関最終用途、その他最終用途）

調査対象企業の例

  • 23andMe
  • Ambry Genetics
  • BGI Genomics
  • Centogene N.V.
  • Color Health, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine
  • Fulgent Genetics
  • GeneDx
  • Genomic Health（a subsidiary of Exact Sciences）
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Myriad Genetics
  • Natera, Inc.
  • NeoGenomics Laboratories
  • Oxford Nanopore Technologies
  • Qiagen
  • Thermo Fisher Scientific

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32666

Global Precision Genomic Testing Market to Reach US$42.3 Billion by 2030

The global market for Precision Genomic Testing estimated at US$16.7 Billion in the year 2024, is expected to reach US$42.3 Billion by 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Genomic Testing Consumables, one of the segments analyzed in the report, is expected to record a 18.2% CAGR and reach US$24.6 Billion by the end of the analysis period. Growth in the Genomic Testing Equipment segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 15.7% CAGR

The Precision Genomic Testing market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 15.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Precision Genomic Testing Market - Key Trends & Drivers Summarized

How Is Precision Genomic Testing Transforming Healthcare?

Precision genomic testing is revolutionizing modern medicine by enabling personalized diagnostics, targeted therapies, and early disease detection. By analyzing an individual's genetic makeup, healthcare providers can tailor treatments based on genetic variations, significantly improving patient outcomes. This approach is particularly impactful in oncology, rare diseases, pharmacogenomics, and reproductive health, where genetic insights play a crucial role in treatment decisions.

The expansion of next-generation sequencing (NGS), CRISPR-based gene editing, and AI-driven bioinformatics has accelerated the adoption of precision genomic testing across various medical fields. Advances in whole genome sequencing (WGS), whole exome sequencing (WES), and liquid biopsy techniques are enhancing diagnostic accuracy, making genomic testing more accessible and cost-effective. As genetic research continues to evolve, the integration of multi-omics approaches-including proteomics and metabolomics-is further refining precision medicine applications.

What Market Trends Are Driving Growth in Precision Genomic Testing?

One of the most significant trends shaping the precision genomic testing market is the increasing demand for personalized medicine. The growing recognition that genetic differences influence drug response has fueled the expansion of pharmacogenomics, which helps determine the most effective medications for individuals based on their genetic profiles. This is particularly important in fields such as oncology, cardiology, and neurology, where genetic factors significantly impact treatment efficacy.

Another key trend is the rising adoption of direct-to-consumer (DTC) genetic testing. Companies offering at-home genomic testing kits for ancestry, disease risk assessment, and lifestyle recommendations have gained popularity, driving market expansion. However, regulatory scrutiny and ethical concerns regarding data privacy remain key challenges in this sector.

Advancements in AI and big data analytics are also transforming the genomic testing landscape. Machine learning algorithms are being used to interpret vast amounts of genomic data, improving the accuracy of disease risk prediction and biomarker discovery. Additionally, cloud-based genomic databases are facilitating large-scale genetic studies, accelerating research into complex diseases and potential therapeutic targets.

Which Regions Are Leading in Precision Genomic Testing Adoption?

North America dominates the precision genomic testing market, driven by strong research funding, high adoption of personalized medicine, and advanced healthcare infrastructure. The United States leads the way with significant investments in genomics research, government initiatives such as the All of Us Research Program, and collaborations between biotech firms and academic institutions.

Europe is also a key player, benefiting from regulatory support, public-private partnerships, and growing awareness of genetic testing’s clinical benefits. Countries like Germany, the UK, and France are advancing precision medicine initiatives, with an emphasis on integrating genomic data into healthcare systems to improve patient care.

Asia-Pacific is experiencing rapid growth in genomic testing, fueled by increasing investments in biotechnology, expanding healthcare access, and government initiatives promoting precision medicine. China, Japan, and South Korea are leading the region’s genomic research efforts, with national programs dedicated to genomic data collection and analysis. Meanwhile, emerging markets in Latin America and the Middle East are gradually adopting precision genomic testing, although challenges such as high costs and limited infrastructure remain barriers to widespread implementation.

The Growth in the Precision Genomic Testing Market Is Driven by Several Factors

One of the primary drivers of market growth is the increasing prevalence of genetic disorders and complex diseases such as cancer, neurodegenerative conditions, and cardiovascular diseases. As early detection and risk assessment become more critical in healthcare, genomic testing is playing an essential role in guiding preventative measures and precision therapies.

Technological advancements in sequencing platforms, including the development of cost-efficient and ultra-fast sequencing techniques, are making genomic testing more accessible. The emergence of portable sequencing devices and automated workflows is further expanding the reach of precision medicine beyond specialized laboratories to clinical settings and point-of-care diagnostics.

Regulatory support and funding initiatives are also accelerating market adoption. Governments worldwide are investing in national genomic databases and precision medicine programs, promoting collaboration between healthcare providers, research institutions, and biotech companies. Additionally, reimbursement policies for genetic testing are evolving, improving affordability and patient access to genomic-based diagnostics.

As the field of genomics continues to advance, the convergence of AI, cloud computing, and molecular biology will further enhance the capabilities of precision genomic testing. With its potential to redefine disease management, drug development, and preventative healthcare, the market is poised for substantial growth, shaping the future of personalized medicine worldwide.

SCOPE OF STUDY:

The report analyzes the Precision Genomic Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Genomic Testing Consumables, Genomic Testing Equipment, Genomic Testing Services); Technology Type (Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology, Other Technology Types); Application (Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • 23andMe
  • Ambry Genetics
  • BGI Genomics
  • Centogene N.V.
  • Color Health, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine
  • Fulgent Genetics
  • GeneDx
  • Genomic Health (a subsidiary of Exact Sciences)
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Myriad Genetics
  • Natera, Inc.
  • NeoGenomics Laboratories
  • Oxford Nanopore Technologies
  • Qiagen
  • Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Precision Genomic Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Personalized Medicine Accelerates Adoption of Precision Genomic Testing
    • Increasing Awareness of Genetic Risk Factors for Disease Drives Growth in Precision Genomic Testing Applications
    • Surge in Preventive Healthcare and Early Disease Detection Expands Market Opportunity for Genomic Testing Solutions
    • Technological Advancements in CRISPR and Gene Editing Propel the Growth of Precision Genomic Testing
    • Growth in Direct-to-Consumer Genetic Testing Services Generates New Market Opportunities for Genomic Testing Providers
    • Rising Prevalence of Chronic Diseases and Cancer Accelerates Demand for Genomic Testing in Disease Prevention
    • Expansion of Genomic Research and Advancements in Bioinformatics Drives Innovation in Precision Genomic Testing
    • Increased Investment in Genomic Data Integration Technologies Strengthens the Case for Genomic Testing in Healthcare
    • Growing Focus on Pharmacogenomics and Tailored Drug Therapies Expands Market Demand for Genomic Testing Solutions
    • Rising Healthcare Expenditure Globally Accelerates Adoption of Precision Genomic Testing in Clinical Practice
    • Growing Popularity of Genetic Testing for Ancestry and Health Traits Drives Market Expansion
    • Integration of Artificial Intelligence and Machine Learning in Genomic Data Analysis Strengthens Adoption of Precision Genomic Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Precision Genomic Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Precision Genomic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Precision Genomic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Genomic Testing Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Genomic Testing Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Genomic Testing Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Genomic Testing Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Genomic Testing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Genomic Testing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Cardiovascular Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Neurological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Neurological Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Reproductive Health Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Reproductive Health Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Rare Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Rare Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Research & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Next-Generation Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Next-Generation Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Polymerase Chain Reaction Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Microarray Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Microarray Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Sanger Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Sanger Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for CRISPR / CAS Systems Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World 6-Year Perspective for CRISPR / CAS Systems Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Other Technology Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 41: World 6-Year Perspective for Other Technology Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 42: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 46: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: USA 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 48: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: USA 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Canada 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 54: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Canada 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • JAPAN
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Japan 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 64: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Japan 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • CHINA
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 66: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 70: China Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: China 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 72: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: China 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • EUROPE
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Precision Genomic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Europe 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 82: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Europe 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • FRANCE
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 84: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 88: France Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: France 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 90: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: France 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • GERMANY
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Germany 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 96: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Germany 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • ITALY
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Italy 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 106: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Italy 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • UNITED KINGDOM
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 108: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 112: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: UK 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 114: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: UK 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of World 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 138: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of World 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030

IV. COMPETITION